Clinical Trial: A Study of LX107 Gene Therapy in AIPL1-IRD Patients

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063030) titled 'A Study of LX107 Gene Therapy in AIPL1-IRD Patients' on July 03.

Brief Summary: Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Retinal Dystrophy

Intervention: GENETIC: LX107 Injection

Subjects will receive subretinal injection of LX107 on Day 0.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Information provided by (Responsible Party): Xiaodong Sun, Shangh...